Abstract
A manufacturer-funded, open-label randomized trial (SPORTIF III) showed the direct thrombin inhibitor ximelagatran (36 mg twice daily) to be as safe and effective as well-controlled warfarin (target INR, 2.0-3.0) for preventing systemic embolism in patients with nonvalvular atrial fibrillation (NVAF) and at least one additional stroke risk …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
